COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma

SIMPLE SUMMARY: The outcome of patients with advanced melanoma has profoundly improved over the last 15 years. Novel medications blocking BRAF, a protein involved in stimulating cell division, or inhibiting immune checkpoints associated with T-cell activation significantly improved overall survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Berking, Carola, Livingstone, Elisabeth, Debus, Dirk, Loquai, Carmen, Weichenthal, Michael, Leiter, Ulrike, Kiecker, Felix, Mohr, Peter, Eigentler, Thomas K., Remy, Janina, Schober, Katharina, Heppt, Markus V., von Wasielewski, Imke, Schadendorf, Dirk, Gutzmer, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526829/
https://www.ncbi.nlm.nih.gov/pubmed/37760406
http://dx.doi.org/10.3390/cancers15184436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526829/
https://www.ncbi.nlm.nih.gov/pubmed/37760406
http://dx.doi.org/10.3390/cancers15184436

Ejemplares similares